Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
27
ERNA Quote, Financials, Valuation and Earnings
Last price:
$1.27
Seasonality move
:
3.2%
Day range:
$1.25 - $1.29
52-week range:
$1.09 - $14.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
37,808.64x
P/B ratio:
2.64x
Volume:
12.8K
Avg. volume:
48.6K
1-year change:
-65.88%
Market cap:
$9.4M
Revenue:
$582K
EPS (TTM):
-$2.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ERNA
Ernexa Therapeutics, Inc.
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ERNA
Ernexa Therapeutics, Inc.
|
$1.28 | -- | $9.4M | -- | $0.00 | 0% | 37,808.64x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.43 | $0.85 | $684.2M | 9.12x | $0.80 | 0% | 10.55x |
|
NNVC
NanoViricides, Inc.
|
$1.25 | $6.50 | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $685.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ERNA
Ernexa Therapeutics, Inc.
|
13.39% | 2.905 | 6.85% | 1.42x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ERNA
Ernexa Therapeutics, Inc.
|
-$70K | -$2M | -5889.53% | -- | -226500% | -$1.3M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Ernexa Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ERNA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -575900% compared to Ernexa Therapeutics, Inc.'s net margin of -255.85%. Ernexa Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ERNAErnexa Therapeutics, Inc.-102.13% -$0.15 $4.1M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ERNA or NBY?
Ernexa Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 70212.47%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.35%. Given that Ernexa Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Ernexa Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ERNAErnexa Therapeutics, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ERNA or NBY More Risky?
Ernexa Therapeutics, Inc. has a beta of 6.200, which suggesting that the stock is 520.041% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ERNA or NBY?
Ernexa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Ernexa Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ERNA or NBY?
Ernexa Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Ernexa Therapeutics, Inc.'s net income of -$1.2M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Ernexa Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ernexa Therapeutics, Inc. is 37,808.64x versus 10.55x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERNAErnexa Therapeutics, Inc.37,808.64x -- -- -$1.2M NBYNovaBay Pharmaceuticals, Inc.10.55x 9.12x $521K -$1.3M
-
Which has Higher Returns ERNA or NNVC?
NanoViricides, Inc. has a net margin of -575900% compared to Ernexa Therapeutics, Inc.'s net margin of --. Ernexa Therapeutics, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital ERNAErnexa Therapeutics, Inc.-102.13% -$0.15 $4.1M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About ERNA or NNVC?
Ernexa Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 70212.47%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 420%. Given that Ernexa Therapeutics, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Ernexa Therapeutics, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ERNAErnexa Therapeutics, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is ERNA or NNVC More Risky?
Ernexa Therapeutics, Inc. has a beta of 6.200, which suggesting that the stock is 520.041% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock ERNA or NNVC?
Ernexa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ernexa Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ERNA or NNVC?
Ernexa Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Ernexa Therapeutics, Inc.'s net income of -$1.2M is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Ernexa Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ernexa Therapeutics, Inc. is 37,808.64x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERNAErnexa Therapeutics, Inc.37,808.64x -- -- -$1.2M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns ERNA or OGEN?
Oragenics, Inc. has a net margin of -575900% compared to Ernexa Therapeutics, Inc.'s net margin of --. Ernexa Therapeutics, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ERNAErnexa Therapeutics, Inc.-102.13% -$0.15 $4.1M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ERNA or OGEN?
Ernexa Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 70212.47%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.07%. Given that Ernexa Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Ernexa Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ERNAErnexa Therapeutics, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is ERNA or OGEN More Risky?
Ernexa Therapeutics, Inc. has a beta of 6.200, which suggesting that the stock is 520.041% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock ERNA or OGEN?
Ernexa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ernexa Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ERNA or OGEN?
Ernexa Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Ernexa Therapeutics, Inc.'s net income of -$1.2M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Ernexa Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ernexa Therapeutics, Inc. is 37,808.64x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERNAErnexa Therapeutics, Inc.37,808.64x -- -- -$1.2M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ERNA or PTN?
Palatin Technologies has a net margin of -575900% compared to Ernexa Therapeutics, Inc.'s net margin of --. Ernexa Therapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ERNAErnexa Therapeutics, Inc.-102.13% -$0.15 $4.1M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ERNA or PTN?
Ernexa Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 70212.47%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Ernexa Therapeutics, Inc. has higher upside potential than Palatin Technologies, analysts believe Ernexa Therapeutics, Inc. is more attractive than Palatin Technologies.
Company Buy Ratings Hold Ratings Sell Ratings ERNAErnexa Therapeutics, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is ERNA or PTN More Risky?
Ernexa Therapeutics, Inc. has a beta of 6.200, which suggesting that the stock is 520.041% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ERNA or PTN?
Ernexa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ernexa Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ERNA or PTN?
Ernexa Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Ernexa Therapeutics, Inc.'s net income of -$1.2M is higher than Palatin Technologies's net income of --. Notably, Ernexa Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ernexa Therapeutics, Inc. is 37,808.64x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERNAErnexa Therapeutics, Inc.37,808.64x -- -- -$1.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ERNA or TOVX?
Theriva Biologics, Inc. has a net margin of -575900% compared to Ernexa Therapeutics, Inc.'s net margin of --. Ernexa Therapeutics, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ERNAErnexa Therapeutics, Inc.-102.13% -$0.15 $4.1M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ERNA or TOVX?
Ernexa Therapeutics, Inc. has a consensus price target of --, signalling upside risk potential of 70212.47%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3528.82%. Given that Ernexa Therapeutics, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe Ernexa Therapeutics, Inc. is more attractive than Theriva Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ERNAErnexa Therapeutics, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ERNA or TOVX More Risky?
Ernexa Therapeutics, Inc. has a beta of 6.200, which suggesting that the stock is 520.041% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock ERNA or TOVX?
Ernexa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ernexa Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ERNA or TOVX?
Ernexa Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Ernexa Therapeutics, Inc.'s net income of -$1.2M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Ernexa Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ernexa Therapeutics, Inc. is 37,808.64x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ERNAErnexa Therapeutics, Inc.37,808.64x -- -- -$1.2M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 5.38% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 1.37% over the past day.
Buy
69
QBTS alert for Dec 23
D-Wave Quantum, Inc. [QBTS] is down 3.36% over the past day.
